Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pexastimogene devacirepvec - SillaJen Biotherapeutics

Drug Profile

Pexastimogene devacirepvec - SillaJen Biotherapeutics

Alternative Names: JX-594; Pexa-Vec; TG-6006

Latest Information Update: 25 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jennerex Biotherapeutics
  • Developer Bergonie Institute; Centre Leon Berard; GC Pharma; Jennerex; Lee's Pharmaceutical; National Cancer Institute (France); National Cancer Institute (USA); Regeneron Pharmaceuticals; SillaJen Biotherapeutics; Transgene; Yonsei University College of Medicine; Yonsei University Health System
  • Class Antineoplastics; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Liver cancer
  • Phase II Breast cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Phase I/II Colorectal cancer; Malignant melanoma
  • Preclinical Gastric cancer
  • No development reported Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 04 Sep 2019 Preclinical trials in Malignant melanoma (Combination therapy) in China (Parenteral)
  • 04 Sep 2019 Lee Pharmaceutical intends to submit IND application for a phase Ib/II trial to the National Medical Products Administration (NMPA) for Malignant melanoma (Combination therapy)
  • 02 Aug 2019 Transgene suspends patient enrolment in the phase III PHOCUS trial in Liver cancer (First-line therapy, Late-stage disease) in Australia, Canada, China, France, Germany, Hong Kong, Israel, Italy, New Zealand, Portugal, Singapore, South Korea, Taiwan, Thailand, USA, United Kingdom as per recommendation by Independent Data Monitoring Committee (IDMC) (Intratumoural) (NCT02562755)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top